Phase II year
1989
(last award dollars: 1990)
The long-term objectives of this project are to identify and characterize cellular receptors for specific oligosaccharides, and to use this information to target therapeutic agents (e.g., proteins) to specific cells. During Phase I, methods to purify high-mannose oligosaccharides were developed. In Phase II, these oligosaccharides will be used for three purposes: (1) preparation of neoglycoproteins for targeting to specific cells, (2) characterization of mannose receptors on immune system cells, and (3) development of new methods for oligosaccharide structural analysis. Technology for purifying individual high-mannose oligosaccharide isomers in quantity will be developed, and methods for coupling these individual oligosaccharides to specific protein amino acids will be explored. Binding of the individual oligosaccharide isomers to the macrophage receptor and to immune system cells will be investigated to determine receptor-binding specificity. The three-dimensional structure of the oligosaccharide isomers will be determined by a combination of NMR and computer modeling studies, and related to the receptor-binding patterns.
Anticipated Results:The project results will allow optimization of the in vivo efficacy of glucocerebrosidase via targeting to macrophages. This product is currently in Phase II clinical trials for treatment of Gaucher's disease. The project results may also lead to new instrumentation for oligosaccharide analysis.National Institute Of General Medical Sciences (NIGMS)